Wang R, Xu Y, Wang B, Wang H, et al. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study. Ann Hematol 2024;103:61-71.
PMID: 37926751